Efficacy of entecavir combined with alprostadil in treatment of hepatitis B-related cirrhotic ascites
-
摘要: 目的观察恩替卡韦与前列地尔联合治疗乙型肝炎肝硬化腹水的临床疗效。方法选取2012年5月-2014年2月德州市中医院收治的乙型肝炎肝硬化腹水患者100例,随机分为治疗组与对照组,每组各50例,两组均常规给予保肝、利尿、间断补充白蛋白(Alb)治疗,其中治疗组加用恩替卡韦0.5 mg口服,1次/d,联合前列地尔20μg+5%葡萄糖注射液100 ml静滴,1次/d,观察组只加用恩替卡韦0.5 mg口服,1次/d。住院治疗4周,观察两组治疗前后腹水消退情况、ALT、TBil、Alb、血液尿素氮(BUN)、肌酐(Cr)、凝血酶原活动度(PTA)、HBV DNA水平变化。出院后两组患者继续口服恩替卡韦0.5 mg,1次/d,随访3个月观察远期疗效。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验。结果两组患者治疗后腹水量较治疗前均有不同程度降低,治疗组总有效率(84%)高于对照组(64%),差异有统计学意义(χ2=6.018,P<0.05);两组患者肝肾功能各项指标(ALT、TBil、Alb、BUN、Cr)及PTA治疗后较治疗前均有不同程度改善,且治疗组疗效优于对照组,两组治疗后各项...Abstract: Objective To investigate the efficacy of entecavir combined with alprostadil in the treatment of hepatitis B- related cirrhotic ascites. Methods A total of 100 patients with hepatitis B- related cirrhotic ascites who were admitted to Dezhou Hospital of Traditional Chinese Medicine from May 2012 to February 2014 were selected and randomly divided into treatment group and control group,with 50 patients in each group. The patients in both groups received the liver- protecting treatment,diuretic treatment,and intermittent supplementation of albumin( Alb). Additionally,the patients in the treatment group received oral entecavir 0. 5 mg once a day,combined with intravenous infusion of alprostadil 20 μg + 5% glucose injection 100 ml once a day,and those in the observation group only received oral entecavir 0. 5 mg once a day. The patients were hospitalized and treated for 4 weeks. Ascites regression,changes in the levels of alanine aminotransferase( ALT),total bilirubin( TBil),Alb,blood urea nitrogen( BUN),creatinine( Cr),and hepatitis B virus( HBV) DNA,and prothrombin activity( PTA) were observed in both groups. After discharge,the patients in both groups continued to take oral entecavir 0. 5 mg once a day,and the long- term therapeutic effect was observed through follow- up for 3 months. The t- test was applied for comparison of continuous data between groups,and the chi- square test was applied for comparison of categorical data between groups. Results The patients in both groups had varying degrees of reduction in the amount of ascites after treatment,and the treatment group had a significantly higher overall response rate than the control group( χ2= 6. 018,P < 0. 05). The patients in both groups had varying degrees of improvement in each index of liver and renal function( ALT,TBil,Alb,BUN,and Cr) and PTA after treatment; the treatment group had a better treatment outcome than the control group,and there were significant differences in each index after treatment between the treatment group and the control group( t = 7. 567,6. 875,- 4. 782,6. 786,8. 542,and 8. 976,all P < 0. 01). The patients in both groups had varying degrees of reduction in HBV DNA level after treatment( t = 8. 976 and 5. 758,both P < 0. 01),but HBV DNA level showed no significant difference between the two groups after treatment( P > 0. 05). The patients were followed up for 3 months after discharge,and the treatment group had a better treatment outcome than the control group in terms of stabilization of liver and renal function and recurrence of ascites. Conclusion Entecavir combined with alprostadil has a good therapeutic effect in hepatitis B- related cirrhotic ascites,as well as a good long- term effect,and is worthy of clinical application. Entecavir monotherapy does not improve renal function significantly,but can improve liver function significantly.
-
Key words:
- liver cirrhosis /
- hepatitis B /
- ascites /
- alprostadil /
- entecavir /
- therapy
-
[1]YU JP.Effect of antiviral therapy for patients with decompensated hepatitis B cirrhosis[J].Chin Hepatol,2013,18(2):132-133.(in Chinese)余佳平.乙型肝炎肝硬化失代偿期患者抗病毒治疗的疗效观察[J].肝脏,2013,18(2):132-133. [2]WANG Y,QIN CZ,SHAO JL.Clinical diagnosis and treatment of liver cirrhosis with refractory ascites:an analysis of 50 cases[J].Chin Foreign Med Res,2013,11(32):18-19.(in Chinese)王毅,秦长忠,邵佳亮.50例肝硬化合并难治性肝腹水的临床诊治分析[J].中外医学研究,2013,11(32):18-19. [3] Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline for prevention and treatment of chronic hepatitis B[J].J Clin Hepatol,2006,22(1):3-15.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南[J].临床肝胆病杂志,2006,22(1):3-15. [4] Branch of Gastrointestinal Diseases,China Association of Chinese Medicine.Expert consensus on standardized TCM diagnosis and treatment of cirrhotic ascites(2011,Hainan)[J].Chin J Integr Tradit West Med,2012,32(12):1693-1696.(in Chinese)中华中医药学会脾胃病分会.肝硬化腹水中医诊疗规范专家共识意见(2011年,海南)[J].中国中西医结合杂志,2012,32(12):1693-1696. [5]TANG SL,LIANG XM,ZHANG GY.Advances in pharmacological action and clinical application of alprostadil injection[J].China Pharm,2012,23(25):2383-2385.(in Chinese)汤晟凌,梁晓美,张国勇.前列地尔注射液的药理作用与临床应用进展[J].中国药房,2012,23(25):2383-2385. [6]WEI AL,GUAN ZJ,LONG FL,et al.Advances in the treatment of chronic severe hepatitis of traditional Chinese and western medicine[J].J Liaoning Univ Tradit Chin Med,2012,14(12):7-9.(in Chinese)伟艾凌,官志杰,龙富立,等.慢性重型肝炎中西医治疗进展[J].辽宁中医药大学学报,2012,14(12):7-9. [7]ZHANG XF.Treatment of severe hepatitis with hepatorenal syndrome:an analysis of 66 cases[J].Shaanxi Med J,2013,42(7):844-845.(in Chinese)张向飞.重型肝炎合并肝肾综合征66例治疗观察[J].陕西医学杂志,2013,42(7):844-845. [8]NI XL,GU DY,HU GH.Effects of alprostadil in the prevention of portal vein thrombosis after splenectomy and devascularization:a historical control study[J].Chin J Hepatobiliary Surg,2014,20(5):351-354.(in Chinese)倪晓凌,顾大镛,胡国华.前列地尔预防脾切除和断流术后门静脉系统血栓形成的历史对照研究[J].中华肝胆外科杂志,2014,20(5):351-354. [9]FANG W,LI H,ZHOU L,et al.Effect of prostaglandin E1 on TNF-induced vascular inflammation in human umbilical vein endothelial cells[J].Can J Physiol Pharmacol,2010,88(5):576-583. [10]ZHANG KQ,LI YY,XIAO YQ,et al.Significance of detection of HBV DNA in liver tissue of serum HBV DNA negative hepatitis B cirrhosis patients[J].World Chin J Dig,2014,22(20):2937-2941.(in Chinese)张克勤,李娅娅,肖影群,等.检测血清HBV DNA阴性的乙型肝炎肝硬化患者肝内HBV DNA的意义[J].世界华人消化杂志,2014,22(20):2937-2941. [11]CHUNG WG,KIM HJ,CHOE YG,et al.Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-nave patients with chronic hepatitis B infection[J].Clin Mol Hepatol,2012,18(2):195-202.
本文二维码
计量
- 文章访问数: 2425
- HTML全文浏览量: 15
- PDF下载量: 430
- 被引次数: 0